trial

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

NCTId NCT03303456
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 79 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2015-11-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
79 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-12-14
Primary completion
2015-11-01
Eligibility
ALL · 13 Years · 30 Years

Interventions & indications

Drugs
Mobile health application - Ginger.io

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Ginger.ioCollaborator

Investigators

1
Tara A Niendam, Ph.D.Principal Investigator

Sites

1 total
Sacramento, United States

Facts & assertions

4 sourced
Enrollment
79
Phase
NA
Primary Completion Date
2015-11-01
Status
COMPLETED
relationships
The graph out of here
drug
Mobile health application - Ginger.io
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Ginger.io
company
indication
Clinical High Risk for Psychosis
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Tara A Niendam, Ph.D.
person